Patency with antiplatelet treatment after vascular access intervention therapy: a retrospective observational study

Mizuno, Tomohito; Nakamura, Motonobu; Satoh, Nobuhiko; Tsukada, Hiroyuki; Matsumoto, Akihiko; Hamasaki, Yoshifumi; Kume, Haruki; Nangaku, Masaomi

doi:10.1186/s41100-018-0184-5

Cited by 5 publications

(5 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2,[4][5][6] Some previous studies have tried to define the variable related factors that are associated with hemodialysis access dysfunction, focusing on the antiplatelet used. [7][8][9][10][11] The 2019 Kidney Disease Outcomes Quality Initiative Guidelines do not recommend using antiplatelets to prevent thrombosis of hemodialysis access. 12 Additionally, few previous publications revealed that antiplatelets did not improve the patency of hemodialysis AVG.…”

Section: Introductionmentioning

confidence: 99%

“…7,13 However, a few publications studied the results of antiplatelets for prolonged patency of hemodialysis access. [7][8][9] Additionally, other few recent studies determined that antiplatelet therapy improved the long-term patency of AVF and AVG, which were treated for access dysfunction. 8,9 As mentioned, factors related to hemodialysis access dysfunction have small issues.…”

Section: Introductionmentioning

confidence: 99%

“…[7][8][9] Additionally, other few recent studies determined that antiplatelet therapy improved the long-term patency of AVF and AVG, which were treated for access dysfunction. 8,9 As mentioned, factors related to hemodialysis access dysfunction have small issues. Additionally, the results of the main related factor, such as the use of antiplatelets, remained controversial.…”

Section: Introductionmentioning

confidence: 99%

“…Endovascular salvage has a high success rate of >90%; however, the average duration of re‐thrombosis was just 6 months 2,4–6 . Some previous studies have tried to define the variable related factors that are associated with hemodialysis access dysfunction, focusing on the antiplatelet used 7–11 . The 2019 Kidney Disease Outcomes Quality Initiative Guidelines do not recommend using antiplatelets to prevent thrombosis of hemodialysis access 12 .…”

Section: Introductionmentioning

confidence: 99%

“…Additionally, few previous publications revealed that antiplatelets did not improve the patency of hemodialysis AVG 7,13 . However, a few publications studied the results of antiplatelets for prolonged patency of hemodialysis access 7–9 . Additionally, other few recent studies determined that antiplatelet therapy improved the long‐term patency of AVF and AVG, which were treated for access dysfunction 8,9 …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

The related factors to the re‐thrombosis of hemodialysis arteriovenous graft after endovascular salvage

Janjindamai

Hongsakul

Sungsiri

et al. 2022

Seminars in Dialysis

View full text Add to dashboard Cite

Background: Only a few issues of the related factors to hemodialysis access dysfunction have been evaluated, and the effects of antiplatelets to improve the patency of hemodialysis access remained controversial. Hence, this study aimed to determine the related factors to the re-thrombosis of arteriovenous grafts (AVGs) after endovascular treatment.Methods: This retrospective study was conducted at a university-affiliated teaching hospital in Southern Thailand. All patients who underwent hemodialysis with thrombosed AVG, who had pharmacomechanical thrombolysis from January 2016 to December 2018, were enrolled. Post-intervention primary patency was analyzed by the Kaplan-Meier method, and the related factors to the re-thrombosis of AVG were evaluated using logistic regression.Results: A total of 157 patients with thrombosed hemodialysis AVG were enrolled.The most common graft location and configuration was a forearm loop graft (65%).Post-intervention primary patency rate at 1, 3, and 6 months were 79.0%, 67.1%, and 54.0%, respectively. Diabetes mellitus (DM) was a significant related factor for re-thrombosis (hazard ratio [HR], 1.89; 95% confidence interval [CI], 1.20-2.98; p = 0.006). A single antiplatelet after the procedure was a protective factor for rethrombosis (HR, 0.58; 95% CI, 0.38-0.89; p = 0.013). The median post-intervention primary patency was 15.7 months in the group of single antiplatelet usage, which was better than that of the non-antiplatelet group (p = 0.012).Conclusion: DM and antiplatelet usage were significant related factors to the rethrombosis of hemodialysis AVG after endovascular salvage.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The related factors to the re‐thrombosis of hemodialysis arteriovenous graft after endovascular salvage

Janjindamai

Hongsakul

Sungsiri

et al. 2022

Seminars in Dialysis

View full text Add to dashboard Cite

show abstract

Blood Clotting Complications in Dialysis

Fadem

2023

Complications in Dialysis

View full text Add to dashboard Cite

Pharmaceutical prevention strategy for arteriovenous fistula and arteriovenous graft failure

et al. 2019

Self Cite

View full text Add to dashboard Cite

Vascular access failure (VAF) is a critical problem in patients undergoing hemodialysis (HD). Importantly, VAF impairs the quality of life in patients undergoing HD while imposing high medical costs. A variety of strategies (e.g., endovascular therapy and surgical reconstruction) for treating VAF have been established. However, strategies for preventing VAF are scarce. In this review, we summarized the available literatures regarding the prevention of VAF in patients undergoing HD with a focus on arteriovenous fistulas and arteriovenous grafts. This review proposes the following three aspects for developing strategies for preventing VAF: (i) early identification of risk factors of VAF (e.g., preoperative vascular conditions, age, sex, ethnicity, and clinical backgrounds), (ii) prophylactic drugs to reduce the risk of VAF, and (iii) early VAF detection through monitoring and surveillance of vascular access, particularly at frequent stenotic sites. A few prophylactic drugs may effectively prevent VAF based on the patient's clinical background. A few prophylactic drugs may effectively prevent VAF based on the patient's clinical background; however, currently, there is no strong evidence on the efficacy of these drugs in reducing the incidence of VAF. Thus, additional large, randomized controlled studies are warranted to establish effective strategies for preventing VAF.

show abstract

Patency with antiplatelet treatment after vascular access intervention therapy: a retrospective observational study

Cited by 5 publications

References 54 publications

The related factors to the re‐thrombosis of hemodialysis arteriovenous graft after endovascular salvage

The related factors to the re‐thrombosis of hemodialysis arteriovenous graft after endovascular salvage

Blood Clotting Complications in Dialysis

Pharmaceutical prevention strategy for arteriovenous fistula and arteriovenous graft failure

Contact Info

Product

Resources

About